Single-dose orally administered quinolone appears to be sufficient antibiotic prophylaxis for radical retropubic prostatectomy.

OBJECTIVE: To evaluate a new prophylaxis routine, which was introduced at our clinic in December 1998, comprising a single oral dose of antibiotic given prior to radical retropubic prostatectomy (RRP). MATERIAL AND METHODS: A total of 60 men scheduled to undergo RRP were included in a prospective study and received antibiotic prophylaxis in the form of a single oral dose of quinolone. Cultures were made from the tip of the catheter and from urine sampled at the time of extraction as well as 1 and 2 weeks post-extraction. The outcome of this prospective study of 60 men was then compared to the total numbers of patients operated on in 1998 (n = 103) and 1999 (n = 140) by means of a retrospective analysis of clinical files. RESULTS: No cases of sepsis occurred. Two weeks after catheter removal, 15/60 patients had persisting bacteriuria. No other signs of infection were detected. Six patients developed a stricture of the anastomotic area during follow-up (mean duration 18.9 months). When the study group was compared to all patients operated on in 1998 and 1999 no increases in the incidence of anastomotic strictures or serious infections or in the length of hospitalization could be detected. CONCLUSION: A single dose of antibiotic given before RRP appears to be sufficient prophylaxis.

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.

PURPOSE: We evaluated whether biennial screening with prostate specific antigen (PSA) only is sufficient to detect prostate cancer while still curable. MATERIALS AND METHODS: In Göteborg, Sweden 9,972 men 50 to 65 years old were randomized to PSA screening. During 1995 and 1996 these men were invited for a first PSA screening and invited during 1997 and 1998 for a second screening. The screening procedure included PSA measurement in all men and in those with a PSA of 3 ng./ml. or greater also it included digital rectal examination, transrectal ultrasound and sextant biopsies. RESULTS: In the first screening 5,854 men participated and 145 cancers were detected. In the second screening 5,267 men participated and 111 cancers were detected. Only 9 interval cancers were diagnosed. In the second screening 102 cancers (92%) were associated with PSA less than 10 ng./ml. Of 465 men with increased PSA and who underwent biopsy with a benign outcome in the first screening 50 had cancer at the second screening. Of 241 men in whom PSA increased between screenings 1 and 2 cancer was detected in 46. None of the 2,950 men with an initial PSA of less than 1 ng./ml. had a PSA of greater than 3 ng./ml. or interval cancer. CONCLUSIONS: In men with a PSA of less than 2 ng./ml. it seems safe to offer repeat screening after 2 years with PSA only. Men with a PSA of 2 to 3 ng./ml. or a value of greater than 3 ng./ml. with negative biopsy may be better served by a shorter screening interval. Thus, different screening intervals are implied depending on baseline PSA.

Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study.

OBJECTIVE: To study the complications and oncological outcome after cryosurgical ablation of the prostate (CSAP). METHODS: Fifty-four patients with prostate cancer were entered into this prospective phase II trial of CSAP. Patients were followed with serum PSA determinations, follow-up biopsies at 3-6 months postoperatively and a questionnaire to assess complications. A PSA of >1 ng/ml or a positive biopsy was interpreted as progression. RESULTS: Mean follow-up was 58.5 months. Patients needed a suprapubic catheter postoperatively for in mean 18 days. Transient penile numbness occurred in 15%. Bothersome sloughing of dead tissue was noticed by 15% of patients and 15% needed a transurethral resection. Nine patients (17%) developed strictures and five patients stone formation in the prostatic urethra. One patient developed a perennial fistula. Thirty-nine out of 43 patients reporting on potency become impotent, nine patients developed a slight stress incontinence and one severe incontinence.At median follow-up, the actuarial progression-free survival was 38.9%. Fourteen out of 50 patients biopsied (28%) had remaining cancer in their prostates. CONCLUSION: High complication rates in combination with poor oncological outcome has made us stop using this treatment modality.